Ca2+ phospholipid-dependent and independent phosphorylation of synthetic peptide substrates by protein kinase C.

PubWeight™: 0.88‹?›

🔗 View Article (PMID 3830167)

Published in Eur J Biochem on March 16, 1987

Authors

S Ferrari, F Marchiori, O Marin, L A Pinna

Articles by these authors

The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat Genet (1999) 4.77

Loss of Nkx2.1 homeobox gene function results in a ventral to dorsal molecular respecification within the basal telencephalon: evidence for a transformation of the pallidum into the striatum. Development (1999) 4.26

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res (2000) 3.02

ISWI is an ATP-dependent nucleosome remodeling factor. Mol Cell (1999) 2.68

Coding sequence and growth regulation of the human vimentin gene. Mol Cell Biol (1986) 2.34

Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ('casein kinase-2'). FEBS Lett (2001) 2.27

The DNA binding site of HMG1 protein is composed of two similar segments (HMG boxes), both of which have counterparts in other eukaryotic regulatory proteins. EMBO J (1992) 2.18

Cloning of the mitogen-activated S6 kinase from rat liver reveals an enzyme of the second messenger subfamily. Proc Natl Acad Sci U S A (1990) 2.09

Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol (2000) 2.06

Protein kinase CK2 phosphorylates and upregulates Akt/PKB. Cell Death Differ (2005) 2.03

Cell migration from the ganglionic eminences is required for the development of hippocampal GABAergic interneurons. Neuron (2000) 1.91

Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem (1998) 1.86

Visual, vestibular and somatosensory contributions to balance control in the older adult. J Gerontol (1989) 1.82

Acf1, the largest subunit of CHRAC, regulates ISWI-induced nucleosome remodelling. EMBO J (2001) 1.81

Prion protein expression in different species: analysis with a panel of new mAbs. Proc Natl Acad Sci U S A (1998) 1.80

Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol (1998) 1.80

Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol (2000) 1.77

The substrate specificity of the protein kinase induced in cells infected with herpesviruses: studies with synthetic substrates [corrected] indicate structural requirements distinct from other protein kinases. Biochim Biophys Acta (1986) 1.71

Efficient gene transfer to airway epithelium using recombinant Sendai virus. Nat Biotechnol (2000) 1.71

Chronic manganese poisoning. Clinical picture and manganese turnover. Neurology (1967) 1.71

Calcium-enriched foods and bone mass growth in prepubertal girls: a randomized, double-blind, placebo-controlled trial. J Clin Invest (1997) 1.70

Osteosarcoma of the limb. Amputation or limb salvage in patients treated by neoadjuvant chemotherapy. J Bone Joint Surg Br (2002) 1.58

Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer (1993) 1.58

An investigation of the substrate specificity of protein phosphatase 2C using synthetic peptide substrates; comparison with protein phosphatase 2A. Biochim Biophys Acta (1990) 1.56

Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities. J Clin Oncol (1997) 1.56

Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol (2003) 1.50

Preoperative therapy versus immediate surgery in nonmetastatic osteosarcoma. J Clin Oncol (2003) 1.46

Selenium status, fatty acids, vitamins A and E, and aging: the Nove Study. Am J Clin Nutr (1994) 1.46

Neoadjuvant chemotherapy for peripheral malignant neuroectodermal tumor of bone: recent experience at the istituto rizzoli. J Clin Oncol (2000) 1.45

The Ste locus, a component of the parasitic cry-Ste system of Drosophila melanogaster, encodes a protein that forms crystals in primary spermatocytes and mimics properties of the beta subunit of casein kinase 2. Proc Natl Acad Sci U S A (1995) 1.45

[ General postural rehabilitation in musculoskeletal diseases: scientific evidence and clinical indications]. Reumatismo (2007) 1.44

Survival in high-grade osteosarcoma: improvement over 21 years at a single institution. Ann Oncol (2009) 1.44

Site specificity of casein kinase-2 (TS) from rat liver cytosol. A study with model peptide substrates. Eur J Biochem (1986) 1.43

Therapy and survival after recurrence of Ewing's tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997. Ann Oncol (2003) 1.42

Further definition of the substrate specificity of the alpha-herpesvirus protein kinase and comparison with protein kinases A and C. Biochim Biophys Acta (1991) 1.41

A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol (2011) 1.40

Absolute alcohol in esophageal vein sclerosis. Gastrointest Endosc (1988) 1.40

Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 1.39

Construction and in vitro functional evaluation of a low-density lipoprotein receptor/transferrin fusion protein as a therapeutic tool for familial hypercholesterolemia. Hum Gene Ther (1999) 1.39

Gene expression profiling in MDS and AML: potential and future avenues. Leukemia (2011) 1.38

Hmg4, a new member of the Hmg1/2 gene family. Genomics (1998) 1.37

Identification of 40 S ribosomal protein S6 phosphorylation sites in Swiss mouse 3T3 fibroblasts stimulated with serum. J Biol Chem (1993) 1.36

Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann Oncol (2011) 1.36

Structural and functional analysis of a growth-regulated gene, the human calcyclin. J Biol Chem (1987) 1.36

Structural relationship between a bacterial developmental protein and eukaryotic PP2C protein phosphatases. Mol Microbiol (1997) 1.35

Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol. Eur J Cancer (2001) 1.34

Evaluation of widely used models for predicting BRCA1 and BRCA2 mutations. J Med Genet (2004) 1.33

Substrate specificity of protein kinase CK2. Cell Mol Biol Res (1994) 1.33

Three cases of human herpesvirus-6 latent infection: integration of viral genome in peripheral blood mononuclear cell DNA. J Med Virol (1993) 1.32

Template-imprinted nanostructured surfaces for protein recognition. Nature (1999) 1.32

Pattern of relapse in patients with osteosarcoma of the extremities treated with neoadjuvant chemotherapy. Eur J Cancer (2001) 1.31

Proteasomal degradation and N-terminal protease resistance of the codon 145 mutant prion protein. J Biol Chem (1999) 1.30

Kinase CK2 inhibition: an update. Curr Med Chem (2013) 1.29

Antidepressant medications and osteoporosis. Bone (2012) 1.28

Different brain correlates for watching real and virtual hand actions. Neuroimage (2001) 1.28

Molecular cloning of a cDNA for a human ADP/ATP carrier which is growth-regulated. J Biol Chem (1987) 1.27

Differential response of embryonic and fetal myoblasts to TGF beta: a possible regulatory mechanism of skeletal muscle histogenesis. Development (1994) 1.25

Degradation of B-Myb by ubiquitin-mediated proteolysis: involvement of the Cdc34-SCF(p45Skp2) pathway. Oncogene (2000) 1.24

Dephosphorylation of phosphopeptides by calcineurin (protein phosphatase 2B). Eur J Biochem (1994) 1.23

Activation of c-myb expression by phytohemagglutinin stimulation in normal human T lymphocytes. Mol Cell Biol (1985) 1.22

A stimulated S6 kinase from rat liver: identity with the mitogen activated S6 kinase of 3T3 cells. EMBO J (1989) 1.22

Targeted integration of human herpesvirus 6 in the p arm of chromosome 17 of human peripheral blood mononuclear cells in vivo. J Med Virol (1995) 1.22

High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study. J Chemother (2002) 1.21

New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. J Med Chem (2000) 1.21

Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities. J Clin Oncol (1993) 1.19

Deficits in memory and hippocampal long-term potentiation in mice with reduced calbindin D28K expression. Proc Natl Acad Sci U S A (1996) 1.19

Two histone fold proteins, CHRAC-14 and CHRAC-16, are developmentally regulated subunits of chromatin accessibility complex (CHRAC). EMBO J (2000) 1.18

Phosphorylation of osteopontin by Golgi apparatus casein kinase. Biochem Biophys Res Commun (1997) 1.18

Protein kinase CK2alpha' is induced by serum as a delayed early gene and cooperates with Ha-ras in fibroblast transformation. J Biol Chem (1998) 1.17

Human herpesvirus-6 in human lymphomas: identification of specific sequences in Hodgkin's lymphomas by polymerase chain reaction. Blood (1991) 1.17

High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study. J Clin Oncol (2002) 1.17

Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways. Leukemia (2012) 1.16

Golgi apparatus mammary gland casein kinase: monitoring by a specific peptide substrate and definition of specificity determinants. FEBS Lett (1996) 1.16

Predictive factors for local recurrence in osteosarcoma: 540 patients with extremity tumors followed for minimum 2.5 years after neoadjuvant chemotherapy. Acta Orthop Scand (1998) 1.16

Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy. Cancer (1993) 1.16

Insulin-stimulated protein kinase B phosphorylation on Ser-473 is independent of its activity and occurs through a staurosporine-insensitive kinase. J Biol Chem (2001) 1.16

Sequential phosphorylation of protein band 3 by Syk and Lyn tyrosine kinases in intact human erythrocytes: identification of primary and secondary phosphorylation sites. Blood (2000) 1.16

Unmasking a growth factor/oncogene-activated S6 phosphorylation cascade. Cell Signal (1989) 1.14

The consensus sequences for cdc2 kinase and for casein kinase-2 are mutually incompatible. A study with peptides derived from the beta-subunit of casein kinase-2. FEBS Lett (1992) 1.14

G1 cell-cycle arrest and apoptosis by histone deacetylase inhibition in MLL-AF9 acute myeloid leukemia cells is p21 dependent and MLL-AF9 independent. Leukemia (2006) 1.13

The nuclear localization domain of the MEF2 family of transcription factors shows member-specific features and mediates the nuclear import of histone deacetylase 4. J Cell Sci (2001) 1.13

Inhibition of Aurora A in response to DNA damage. Oncogene (2006) 1.13

Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro. J Pharmacol Exp Ther (2001) 1.13

Do RANKL inhibitors (denosumab) affect inflammation and immunity? Osteoporos Int (2010) 1.12

Regulation of B-Myb activity by cyclin D1. Oncogene (2000) 1.12

Inhibition of protein kinase CK2 suppresses angiogenesis and hematopoietic stem cell recruitment to retinal neovascularization sites. Mol Cell Biochem (2008) 1.12

Chondrosarcoma of the temporomandibular joint: a case report and review of the literature. J Oral Maxillofac Surg (1997) 1.12

Crystal structure of the catalytic subunit of protein kinase CK2 from Zea mays at 2.1 A resolution. EMBO J (1998) 1.12

Novel consensus sequence for the Golgi apparatus casein kinase, revealed using proline-rich protein-1 (PRP1)-derived peptide substrates. Biochem J (2000) 1.12